These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20574050)

  • 41. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
    Tacchetti P; Terragna C; Galli M; Zamagni E; Petrucci MT; Pezzi A; Montefusco V; Martello M; Tosi P; Baldini L; Peccatori J; Ruggieri M; Pantani L; Lazzaro A; Elice F; Rocchi S; Gozzetti A; Cavaletti G; Palumbo A; Cavo M
    Am J Hematol; 2014 Dec; 89(12):1085-91. PubMed ID: 25159313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
    Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.
    Abraham RS; Ballman KV; Dispenzieri A; Grill DE; Manske MK; Price-Troska TL; Paz NG; Gertz MA; Fonseca R
    Blood; 2005 Jan; 105(2):794-803. PubMed ID: 15388584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
    Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
    Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
    Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
    Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
    [No Abstract]   [Full Text] [Related]  

  • 49. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
    Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
    J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
    Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
    APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
    Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
    Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
    Goldschmidt H; Lokhorst HM; Mai EK; van der Holt B; Blau IW; Zweegman S; Weisel KC; Vellenga E; Pfreundschuh M; Kersten MJ; Scheid C; Croockewit S; Raymakers R; Hose D; Potamianou A; Jauch A; Hillengass J; Stevens-Kroef M; Raab MS; Broijl A; Lindemann HW; Bos GMJ; Brossart P; van Marwijk Kooy M; Ypma P; Duehrsen U; Schaafsma RM; Bertsch U; Hielscher T; Jarari L; Salwender HJ; Sonneveld P
    Leukemia; 2018 Feb; 32(2):383-390. PubMed ID: 28761118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.
    Warnnissorn AN; Treetipsatit J; Limvorapitak W
    Hematology; 2020 Dec; 25(1):292-298. PubMed ID: 32772824
    [No Abstract]   [Full Text] [Related]  

  • 54. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
    Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
    Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
    Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
    Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma.
    Shin SY; Jang S; Park CJ; Chi HS; Lee JH; Lee JH; Lee KH; Suh C; Lim SE; Seo EJ
    Int J Lab Hematol; 2012 Oct; 34(5):541-6. PubMed ID: 22672327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
    Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
    Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.